



Accessibility, Affordability & Equitable Distribution of Covid- 19 vaccines & Therapeutics

Makomani SIYANGA
22 September 2022

Outline

Background

Universal Health Coverage

Covid 19 Vaccine & Therapeutics Global Outlook

Global Equitable Access To Covid-19 Vaccines

Regulatory and Manufacturing Capacity

Local Production of medicines

Background

- Zambia Medicines Regulatory Authority (ZAMRA) is a technical arm of the Ministry of Health and it draws its mandate from the Medicines and Allied Substances Act (No.3) of 2013.
- The Authority is a semi-autonomous statutory body
- Functions of the Authority include:
 1. Grant of Marketing Authorization of Medicines and Allied Substances
 2. Authorisation and monitoring of Clinical Trials involving medicines or allied substances
 3. Licensing of Pharmaceutical facilities
 4. Inspection of Pharmaceutical facilities
 5. Monitoring of Medicines or Allied Substances throughout the Supply Chain
 6. Quality control testing of Medicines and Allied Substances

Universal Health Coverage

- **Good health by All** is a right that should that every government should provide or facilitate.
- **Universal Health Coverage (UHC)** entails ensuring all people have access to quality health services – including prevention, promotion, treatment, rehabilitation, and palliation – without incurring financial hardship.
- The concept covers three key elements:
 - **Access,**
 - **Quality, and**
 - **Financial Protection.**

Covid 19 Vaccine & Therapeutics



41

vaccines approved for use by at least one national regulatory authority¹



11

vaccines in WHO's Emergency Use Listing



1.75bn

doses shipped through COVAX to 146 countries



\$2-\$40

reported vaccine price range per dose



17.6bn

doses secured globally



21K

novel oral antiviral therapeutic treatments arrived in 1 countries

Global Equitable Access To Covid-19 Vaccines

- COVAX has been the vaccines pillar of the **Access to COVID-19 Tools (ACT)** Accelerator.
- The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
- COVAX is co-led by the **Coalition for Epidemic Preparedness Innovations (CEPI)**, Gavi and the **World Health Organization (WHO)**, alongside key delivery partner UNICEF.
- It aims to accelerate the **development and manufacture of COVID-19 vaccines** and to guarantee fair and equitable access for every country in the world.
- WHO has multiple roles within COVAX: It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery.

Regulatory and Manufacturing Capacity

- Capacity of national drug regulatory system is cardinal to support access, affordability and distribution of vaccines and therapeutics.
- Regional collaboration and harmonisation is key in achieving a good regulatory system of country.
- Aspiration is to attain **WHO GBT ML3** in order to stimulate and support local; and participate in regional production of the medical products.
- Eventually aim to attain **WHO GBT ML4** for vaccines production
- Countries should strive to enter into agreements/ MoUs in order to actualise access, affordability and distribution.
- Reliance and mutual recognition are a cornerstone for regulatory systems that weak and poorly resourced.

Stimulating Local Production of Therapeutics

- Establishment of a multi-disciplinary committee which include:
 - Ministry of Health
 - ZAMRA (NDRA)
 - EU (Consultants)
 - Ministry of Commerce Trade and Industry (MCTI)
 - Academia
 - Others
- Establishment four (4) TWG:
 - Legal and Policy
 - Research ,Development and Technology Transfer
 - Regulation and Quality Assurance
 - Investment Promotion - Finance Mechanism/Access To Finance

Cont'd

- Development of the **Pharmaceutical Strategy**

Thank You